Calidi Biotherapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Calidi Biotherapeutics Inc 's ROA in the second quarter of 2026?
Calidi Biotherapeutics Inc recorded a cumulative net loss of $-18 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -176.49%.

However, within the Healthcare sector 832 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4463, from total ROA ranking in the first quarter of 2026 at 5137.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-22.96 %	-99.98 %	-39.83 %	110.74 %	45.41 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-18	-19	-20	-18	-18
Return On Assets (TTM)	-176.49 %	-182.74 %	-0.16 %	-0.15 %	-0.15 %
CLDI's Total Ranking	# 4463	# 5137	# 4498	# 4613	# 4733
Total Assets (TTM) in million	7	10	9	14	9
Seq. Total Assets Change	-24.89 %	8.29 %	-36.87 %	50.03 %	-99.98 %
Seq. Net Income Change	-	-	-	-	-

CLDI's 5 Years Annual ROA >> Back to CLDI Management Effectiveness >> Compare CLDI ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 129
Sector	# 833
Overall	# 4403

Return On Assets Statistics
High	Average	Low
3.77 %	-158.79 %	-530.03 %
(Sep 30 2022)		(Sep 30 2024)

News about Calidi Biotherapeutics Inc Return on Assets ROA

Dr. Mark Gilbert Joins Calidi Biotherapeutics' Medical Advisory Board, Bringing In-Depth Government Healthcare Agency Expertise

Introduction
In a recent press release, Calidi Biotherapeutics Inc, a leading biopharmaceutical company focused on developing innovative cell-based immunotherapies, announced the appointment of Dr. Mark Gilbert to its esteemed Medical Advisory Board. Dr. Gilbert, a former neuro-oncology leader at the renowned National Institutes of Health (NIH) and National Cancer Institute (NCI), brings with him a wealth of experience and expertise in government healthcare agencies. This strategic addition aims to bolster Calidi Biotherapeutics position in the healthcare sector and drive its growth amidst recent challenges.
Calidi Biotherapeutics Inc s Declining Shares and Cumulative Net Loss
Over the past five trading days, Calidi Biotherapeutics Inc shares have faced a decline of -25.64%. These market fluctuations reflect the challenges faced by the company in a highly competitive and fast-paced industry. Additionally, during the 12 months ending in the first quarter of 2024, Calidi Biotherapeutics Inc recorded a cumulative net loss of $34 million, resulting in a negative return on assets (ROA) of -171.04%. This financial setback represents the difficulties encountered during the company s journey to achieve profitability and market dominance.

Financial Statements
Calidi Biotherapeutics Inc 's Assets	$ 7 million	CLDI's Balance sheet
Calidi Biotherapeutics Inc 's Income	$ -4 million	Quarterly CLDI's Income Statement
CLDI's Income by Division		See CLDI's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-37.55 %	41.55 %	-76.37 %	-81.7 %	-
Total Assets in million	9	14	10	42	232
Y / Y Net Income Change	-	-	-	4.24 %	-
Net Income in million	-20	-22	-29	4	3
Annual Return On Assets	-226.52 %	-156.6 %	-291.61 %	8.33 %	1.46 %

CLDI's 5 Years Annual ROA >> Back to CLDI Management Effectiveness >> Compare CLDI ROA to its Competitors

More Return On Assets Ratios
CLDI's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CLDI's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CLDI's Competitors
Subscribers only: Roa for Calidi Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CLDI's Customers

You may also want to know
CLDI's Roi	CLDI's Inventory Turnover Ratio	CLDI's Growth Rates	CLDI's Dividend Comparisons
	CLDI's Profitability Ratios	CLDI's Asset Turnover Ratio	CLDI's Dividend Growth
CLDI's Roe	CLDI's Valuation Ratios	CLDI's Financial Strength Ratios	CLDI's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-02T20:40:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.